查詢結果分析
相關文獻
- Clinicopathologic Findings and Outcome in Lupus Nephritis Patients with Renal Biopsy
- 硬皮症合併全身紅斑性狼瘡與眼底疑似色素性視網膜炎的眼睛表現--病例報告
- Cutaneous Mycobacterium kansasii Infection in a Patient with Systemic Iupus Erythematosus: Diagnosed by Genotyping and Phenotyping
- Tc-99m DTPA Aerosol Lung Clearance Test in Systemic Lupus Erythematosus
- The Relationship of Alveolar Permeability and Pulmonary Inflammation in Patients with Systemic Lupus Erythematosus
- 一位全身紅斑性狼瘡病患脫離呼吸器之護理經驗
- 全身紅斑性狼瘡腎炎治療的新進展
- 全身紅斑性狼瘡的認識與迷思
- 全身紅斑性狼瘡的認識與迷思
- 全身紅斑性狼瘡之治療現況
頁籤選單縮合
題 名 | Cutaneous Mycobacterium kansasii Infection in a Patient with Systemic Iupus Erythematosus: Diagnosed by Genotyping and Phenotyping=全身紅斑性狼瘡病人之皮膚Mycobacterium kansasii感染:藉由基因鑑定和型態鑑定診斷 |
---|---|
作 者 | 邱政偉; 林俞志; 王綺嫻; 邱顯清; | 書刊名 | 中華皮膚科醫學雜誌 |
卷 期 | 21:2 2003.06[民92.06] |
頁 次 | 頁160-164 |
分類號 | 415.761 |
關鍵詞 | 全身紅斑性狼瘡; Mycobacterium kansasii; Heat shock protein 65; HSP65; |
語 文 | 英文(English) |
中文摘要 | Mycobacterium kansasii引起的皮膚感染相當少見而且在臨床和組織學上的表現相當多樣。大多數感染M. kansasii的病人免疫系統多有異常:可能來自使用免疫抑制劑或有其他內在疾病。實驗室鑑別致病菌對於確立診斷和使用正確的抗分技桿菌藥物相當重要。我們報告一例全身紅斑狼瘡之病人皮膚感染M. kansasii。DNA由皮膚切片的檢體抽取出來,HSP65基因的一部份經由聚合脢鏈鎖反應(PCR)放大。放大產物經由直接定序的結果和M. kansasii的序例資料相符合。皮膚切片去做組織培養在八個禮拜後也長出M. kansasii。診斷確立後病人接受isoniazid,ethambutol和rifampin之治療。在開始併用三種藥物治療之後的三個月內,沒有新的皮膚病灶再出現。 |
英文摘要 | Mycobacterium kansasii infections of the skin are rarely seen and present variable clinical and histologic features. Most patients with M. kansasii infection have altered immunity, caused either by immunosuppressants or underlying diseases. Laboratory identification of the organism is essential for proper diagnosis and selection of appropriate antimycobacterial medication. We report cutaneous M. kansasii infection in a patient with systemic lupus erythematosus. DNA was extracted from skin biop- sy specimen and a portion of HSP65 gene was amplified by polymerase chain reaction(PCR). The DNA sequence of the amplified product was compatible with that of M. kansasii. Culture of the skin biopsy specimen also yielded M. kansasii in 8 weeks. Treatment including isoniazid, ethambutol and rifampin was insititued right after the diagnosis was established. No new lesions have been noted for three months after initiation of the three combined therapy. |
本系統中英文摘要資訊取自各篇刊載內容。